Table 1.
Patient details.
| N | Age at OP | Sex | Disease duration (y) | UPDRS-III preop OFF/ON | UPDRS-III Baseline** mOFF/mON | UPDRS-III 3 months** FU mOFF/mON | UPDRS-III 8 months** FU mOFF/mON | Medication (LED) at 8 months FU | DBS effect at 8 months FU (% preop UPDRS) | Stimulation parameters at 8 months FU |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 63 | M | 10 | 46/26 | 43.5/16.5 | 34.5/25.5 | 35.5/24 | 1375 mg | 68 | L: 2-, 2 V; R: 2-,2.2 V; 60 μs; 130 Hz |
| 2 | 63 | M | 15 | 49/35 | 25/20.5 | 26/25 | 25.5/25 | 105 mga | 56 | L: 2-, 3 V; 2-,3-, 3.2 V; 60 μs; 130 Hz |
| 3 | 63 | F | 8 | 56/16 | 24/15.5 | 48/31.5 | 42/24 | 665 mg | 62 | L: 3-, 3.2 V; R: 1-, 3.5 V; 60 μs; 130 Hz |
| 4 | 66 | M | 8 | 26/17 | 28/29 | 20/18.5 | 19.5/12.5 | 1064 mg | 48 | L: 1-, 1.5 V; R: 1-, 3.3 V; 60 μs; 130 Hz |
| 5 | 73 | M | 9 | 35/20 | 23/17 | 33/22.5 | 27/18.5 | 1450 mg | 56 | L: 2-, 3.8 V; R: 2–3.9 V; 60 μs; 130 Hz |
| 6 | 63 | M | 16 | 42/29 | 36/32 | 26.5/29 | 39.5/29 | 950 mg | 57 | L: 1-,2-, 3.5 V; R: 1-,2–1.8 V; 60 μs; 130 Hz |
| 7 | 72 | F | 5 | 34/19 | 31/31 | 25.5/20 | 25/14 | 360 mga | 41 | L: 2-, 3.8 V; R: 1–3.9 V; 60 μs; 130 Hz |
| 8 | 61 | F | 10 | 20/4 | 19.5/13 | 18.5/20 | 21.5/13.5 | 500 mg | 43 | L: 2-, 3 V; R: 2–1 V; 60 μs; 130 Hz |
| 9 | 58 | F | 7 | 34/24 | 24/16 | 32.5/27.5 | 37/23.5 | 52 mga | 43 | L: 2-, 3 V; R: 2–1.8 V; 60 μs; 130 Hz |
| 10 | 56 | M | 18 | 41/20 | 20/16 | 51.5/33.5 | 41/17.5 | 665 mg | 45 | L: 1-, 2.2 V; R: 1–3.5 V; 60 μs; 130 Hz |
| 11 | 63 | M | 9 | 31/14 | 19/15.5 | 18/12 | 17/13.5 | 1207 mg | 60 | L: 1–2.8 V; R: 1–2.7 V; 60 μs; 130 Hz |
| 12 | 60 | M | 7 | 59/32 | 28.5/10 | 35/26.5 | 31.5/20 | 1325 mg | 80 | L: 1-, 3 V; R: 1-, 3.2 V; 60 μs; 130 Hz |
| Mean | 63.2 | 4 F | 10.2 | 27/19 | 31/24 | 30/20 | 817.2 mg | 54.9% |
**
All UPDRS-III scores were obtained at the time of recording after at least 30 min OFF DBS.
a
Cases 2/7/9 were on pramipexole treatment (1.05 mg/0.35 mg/1.4 mg); LED = Levodopa Equivalent Dose.